Compare CYTK & CACI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CYTK | CACI |
|---|---|---|
| Founded | 1997 | 1962 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.4B | 11.5B |
| IPO Year | 2004 | 2007 |
| Metric | CYTK | CACI |
|---|---|---|
| Price | $78.68 | $467.13 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 19 | 12 |
| Target Price | $89.26 | ★ $689.50 |
| AVG Volume (30 Days) | ★ 1.7M | 229.1K |
| Earning Date | 05-05-2026 | 04-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.00 |
| EPS | N/A | ★ 17.11 |
| Revenue | $13,368,000.00 | ★ $4,467,860,000.00 |
| Revenue This Year | $7.37 | $12.42 |
| Revenue Next Year | $310.19 | $10.00 |
| P/E Ratio | ★ N/A | $29.07 |
| Revenue Growth | N/A | ★ 2.60 |
| 52 Week Low | $31.99 | $445.48 |
| 52 Week High | $80.20 | $683.50 |
| Indicator | CYTK | CACI |
|---|---|---|
| Relative Strength Index (RSI) | 62.37 | 29.38 |
| Support Level | $59.07 | N/A |
| Resistance Level | $79.66 | $511.94 |
| Average True Range (ATR) | 3.20 | 19.94 |
| MACD | 0.51 | -4.35 |
| Stochastic Oscillator | 83.65 | 7.61 |
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
CACI International Inc is an information solutions and services provider, offering information solutions and services to its customers. The company's primary customers are agencies and departments of the U.S. government, which account for the vast majority of the firm's revenue. It provides information solutions and services supporting national security missions and government modernization for intelligence, defense, and federal civilian customers. Some of the services provided by the company are functional software development, data, and business analysis, IT operations support, naval architecture, and life cycle support intelligence among others. The company's operating segments are; Domestic operations and International operations. It derives key revenue from the Domestic segment.